House Rx, a healthcare technology company focused on improving access and affordability for specialty medications, has raised $55 million in Series B equity and debt financing to grow its in-clinic specialty pharmacy model. The round was led by New Enterprise Associates and Town Hall Ventures with participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. With this new funding, the company has now raised a total of $100 million.
Health Technology Insights: Digital Initiative Strengthens Access to Mental Health Support
As regulators and states challenge the traditional Pharmacy Benefit Manager-owned, closed network specialty pharmacy model, House Rx offers a different approach. Its model centers on a nationwide network of locally operated specialty pharmacies embedded within specialty clinics. This approach allows patients and healthcare providers to work together closely and delivers higher quality outcomes. By integrating pharmacy services directly into clinics, House Rx helps providers offer personalized alternatives to centralized fulfillment, reduces administrative burden, and improves coordination between pharmacists and healthcare teams, resulting in better care for patients managing complex conditions.
“Finally, we are seeing momentum behind creating a specialty pharmacy system that makes it easier for patients to access the medications they need affordably and efficiently,” said Ogi Kavazovic, CEO and Founder of House Rx. “Stakeholders across the healthcare ecosystem including providers, manufacturers, payers, and investors recognize the need to challenge the current system. With this funding, we are ready to scale our operations to meet growing demand and help reduce costs for patients and the healthcare system.”
Health Technology Insights: Corvus Launches to Streamline Surgical Referrals and Access to Care
House Rx has already partnered with over 1,000 providers across 80 clinic locations nationwide, supporting the launch and management of in-house pharmacies that improve patient outcomes. The company currently manages roughly $1.5 billion in specialty prescriptions annually, with projections to reach $3 billion by the end of 2026.
“Specialty pharmacy has long been one of the most expensive and opaque areas in healthcare, and it is overdue for meaningful change,” said Blake Wu, Partner at NEA. “House Rx combines clinical expertise with technology to make in-clinic specialty pharmacy services more accessible and cost-effective. Their team of pharmacists and software developers is uniquely positioned to transform how complex medications are delivered to patients.” House Rx serves as the pharmacy management system of record for medically integrated dispensaries and includes AI-driven workflows to increase efficiency and reduce administrative work. In April, the company introduced its “Smart PA” feature, which automates 80 percent of prior authorizations, and additional AI capabilities are currently in development.
“The House Rx platform combines software and clinical services to ensure patients can start critical treatments in days rather than weeks,” said David Whelan, Co-Founder and General Partner at Town Hall Ventures. “With urgent needs for improved patient access and medication adherence, the solutions House Rx provides have never been more necessary. We are excited to support Ogi and his experienced team in their mission to return providers and patients to the center of the specialty pharmacy experience.”
Health Technology Insights: FDA Approves Interchangeable Status for Fresenius Kabi Biosimilars
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
